SE454778B - Hydantoinderivat, sett for framstellning derav och farmaceutisk komposition innehallande dem - Google Patents

Hydantoinderivat, sett for framstellning derav och farmaceutisk komposition innehallande dem

Info

Publication number
SE454778B
SE454778B SE8104456A SE8104456A SE454778B SE 454778 B SE454778 B SE 454778B SE 8104456 A SE8104456 A SE 8104456A SE 8104456 A SE8104456 A SE 8104456A SE 454778 B SE454778 B SE 454778B
Authority
SE
Sweden
Prior art keywords
hydantoin derivative
spiro
hydrogen atom
dione
salt
Prior art date
Application number
SE8104456A
Other languages
English (en)
Swedish (sv)
Other versions
SE8104456L (sv
Inventor
K Ueda
S Tanaka
T Kunii
K Kagei
T Sato
H Ono
I Ohtsuka
M Kawase
T Ohgoh
T Wakabayashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of SE8104456L publication Critical patent/SE8104456L/xx
Publication of SE454778B publication Critical patent/SE454778B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE8104456A 1980-07-21 1981-07-20 Hydantoinderivat, sett for framstellning derav och farmaceutisk komposition innehallande dem SE454778B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55098695A JPS5745185A (en) 1980-07-21 1980-07-21 Hydantoin derivative and its preparation

Publications (2)

Publication Number Publication Date
SE8104456L SE8104456L (sv) 1982-01-22
SE454778B true SE454778B (sv) 1988-05-30

Family

ID=14226632

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8104456A SE454778B (sv) 1980-07-21 1981-07-20 Hydantoinderivat, sett for framstellning derav och farmaceutisk komposition innehallande dem

Country Status (14)

Country Link
US (3) US4540704A (ja)
JP (1) JPS5745185A (ja)
BE (1) BE889698A (ja)
CA (1) CA1167447A (ja)
CH (1) CH651568A5 (ja)
DE (1) DE3128606A1 (ja)
DK (1) DK157301C (ja)
ES (1) ES8205398A1 (ja)
FR (1) FR2487353B1 (ja)
GB (1) GB2080304B (ja)
IT (1) IT1194143B (ja)
NL (1) NL8103432A (ja)
PH (1) PH17460A (ja)
SE (1) SE454778B (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
GB2132484B (en) * 1982-12-23 1986-07-02 Tampax Ltd Tampon applicator
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
ATE37371T1 (de) * 1984-08-20 1988-10-15 Pfizer Verfahren zur herstellung asymmetrischer hydantoine.
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US4666931A (en) * 1984-12-29 1987-05-19 Kaken Pharmaceutical Co., Ltd. Benzofuran derivatives useful in treating diabetic complications
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
WO1987004344A1 (en) * 1986-01-17 1987-07-30 Pfizer Inc. Hydroxyacetic acid derivatives for the treatment of diabetic complications
JPS6357588A (ja) * 1986-08-28 1988-03-12 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
EP0264586B1 (en) * 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
JP2708507B2 (ja) * 1988-04-07 1998-02-04 株式会社三和化学研究所 （ｄ）‐６‐フルオロ‐２，３‐ジヒドロ‐２’，５’‐ジオキソ‐スピロ［４Ｈ‐１‐ベンゾピラン‐４，４’‐イミダゾリジン］‐２‐カルボキサミド誘導体、これらの製法及び用途
US4987231A (en) * 1989-08-04 1991-01-22 Pfizer Inc. Optical resolution method for 3R-(3-carboxybenzyl)-6-(5-fluoro-2-benzothiazolyl)methoxy-4R-chromanol
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
WO1993005045A1 (en) * 1991-08-28 1993-03-18 The Upjohn Company Spirocyclic benzopyran imidazolines
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6539336B1 (en) * 1996-12-12 2003-03-25 Phatrat Technologies, Inc. Sport monitoring system for determining airtime, speed, power absorbed and other factors such as drop distance
US7386401B2 (en) * 1994-11-21 2008-06-10 Phatrat Technology, Llc Helmet that reports impact information, and associated methods
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
WO1998046243A2 (en) * 1997-04-15 1998-10-22 Csir Pharmaceutical compositions having appetite suppressant activity
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
AU754989B2 (en) * 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EP1337272A2 (en) 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8158667B2 (en) 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
WO2010065024A1 (en) * 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
NZ594230A (en) 2009-03-13 2013-11-29 Vitae Pharmaceuticals Inc Inhibitors of beta-secretase
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US418729A (en) * 1890-01-07 Cultivator
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
FR2455046A1 (fr) * 1979-04-25 1980-11-21 Science Union & Cie Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament

Also Published As

Publication number Publication date
ES504103A0 (es) 1982-06-01
DE3128606C2 (ja) 1992-04-23
US4874869A (en) 1989-10-17
SE8104456L (sv) 1982-01-22
JPS5745185A (en) 1982-03-13
IT1194143B (it) 1988-09-14
BE889698A (fr) 1982-01-22
DK157301C (da) 1990-05-07
FR2487353B1 (fr) 1986-03-07
DK323281A (da) 1982-02-26
GB2080304B (en) 1984-02-01
PH17460A (en) 1984-08-29
IT8123026A0 (it) 1981-07-20
ES8205398A1 (es) 1982-06-01
FR2487353A1 (fr) 1982-01-29
DE3128606A1 (de) 1982-05-13
CA1167447A (en) 1984-05-15
NL8103432A (nl) 1982-02-16
CH651568A5 (de) 1985-09-30
US4540704A (en) 1985-09-10
US4780472A (en) 1988-10-25
JPS6332793B2 (ja) 1988-07-01
GB2080304A (en) 1982-02-03
DK157301B (da) 1989-12-04

Similar Documents

Publication Publication Date Title
SE454778B (sv) Hydantoinderivat, sett for framstellning derav och farmaceutisk komposition innehallande dem
US4904797A (en) Process of preparing cycloalkano(1,2-B)indole-sulphonamides
KR100191774B1 (ko) 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
US5124350A (en) Leukotriene b4 antagonists
EP0187387B1 (en) Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same
JPH06506467A (ja) 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター
US5079258A (en) Tetrahydro-1-benz-(c,d)-indolepropionic acid sulphonamides as thrombocyte aggregation inhibitors
CS208129B2 (en) Method of preparation of the new spiro-oxazolidindions
JP3036853B2 (ja) 炎症性腸疾患治療に有用な化合物
DK157545B (da) Analogifremgangsmaade til fremstilling af 4-fenyl-1-hydroxyalkylimidazolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4996204A (en) Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992014719A1 (en) Thiazolidine-2,4-dione derivative, salt thereof, and production of the same
US4988820A (en) Cycloalkano(1,2-B) indole-sulponamides
CA2241893A1 (en) 2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity
US4209527A (en) Benzimidazolone derivatives
AU653444B2 (en) Thiadiazinone
CN111620816A (zh) 螺桨烷类衍生物、其制备方法、药物组合物和用途
US4464385A (en) Treatment of diabetic complications with hydantoins
CN111592558B (zh) 具有尿酸再吸收抑制作用的杂环化合物
JPH069392A (ja) 免疫調節剤
FR2639944A1 (fr) Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0261674B1 (en) A cyclohexanedione derivative and a process for producing the same
FR2541276A1 (fr) Derives du dithiolane, leur preparation et compositions pharmaceutiques contenant ces derives
JPH0451527B2 (ja)
JPH0377875A (ja) チアゾリジン‐２，４‐ジオン誘導体およびその製造法

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8104456-2

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8104456-2

Format of ref document f/p: F